Micrometastatic bone marrow involvement: Detection and prognostic significance

Medical Oncology

Volumn 16, Issue 3, 1999, Pages 154-165

  Braun, S ^a   Pantel, K ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Adjuvant therapy; Bone marrow; Micrometastases; Solid tumors; Tumor staging

Indexed keywords

CARBOPLATIN; CYTOKERATIN; EPIRUBICIN; EPITHELIAL MEMBRANE ANTIGEN; GLYCOPROTEIN; IFOSFAMIDE; MONOCLONAL ANTIBODY; MUCIN; VINBLASTINE;

BONE MARROW METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CELL HETEROGENEITY; COLORECTAL CANCER; HUMAN; IMMUNOASSAY; IMMUNOCYTOCHEMISTRY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 0032879715     PISSN: 07360118     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02906127     Document Type: Review

References (89)

1. Black RJ, Bray F, Ferlay J, Parkin DM. Cancer incidence and mortality in die European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997; 33: 1075-1107.
2. Pantel K. Detection of minimal disease in patients with solid tumors. J Hematother 1996; 5: 359-367.
3. Fidler IJ, Radinsky R. Genetic control of cancer metastasis. J Natl Cancer Inst 1990; 82: 166-168.
4. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64: 327-336.
5. Schlimok G et al. Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci USA 1987; 84: 8672-8676.
6. Mansi JL et al. Micrometastasis in bone marrow in patients with primary breast cancer: evaluation as an early predictor of bone metastasis. Br Med J 1987; 295: 1093-1096.
7. Braun S, Pantel K. Prognostic significance of micrometastatic bone marrow involvement. Breast Cancer Res Treat 1998; 52: 201-216.
8. Pantel K et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993; 85: 1419-1424.
9. Slamon JD et al. Addition of Herceptin™ (humanized anri-HER2 antibody) to first-line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anti-cancer activity: a randomized, multinational controlled phase III trial. Proc American Society of Oncology 1998; 17: 98 (abstr 377.)
10. Baselga J et al. Phase II study of weekly intravenous recombinant humanized anti-p 185Her2 monoclonal antibody in patients with Her2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737-744.
11. Riethmüller G et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes C colorectal carcinoma. Lancet 1994; 343: 1177-1183.
12. Salvadori B et al. Use of monoclonal antibody MBr1 to detect micrometastasis in bone marrow specimens of breast cancer patients. Eur J Cancer 1990; 26: 865-867.
13. Courtemanche DJ, Worth AJ, Coupland RW, Rowell JL, MacFarlane JK. Monoclonal antibody LICR-LON-M8 does not predict the outcome of operable breast cancer. Can J Surg 1991; 34: 21-26.
14. Mathieu MC et al. Immunohistochemical staining of bone marrow biopsies for detection of occult metastasis in breast cancer. Breast Cancer Res Treat 1990; 15: 21-26.
15. Mansi JL et al. Bone marrow micrometastasis in primary breast cancer: prognostic significance after 6 years' follow-up. Eur J Cancer 1991; 27: 1552-1555.
16. Gogas H, Mansi JL, Bliss J, Coomes RC. Can the presence of micrometastasis in primary breast cancer predict outcome? Long-term (median 12.5 yrs) follow-up. Proc American Society of Oncology 1997; 16: 153a (abstract #537).
17. Kirk SJ et al. The prognostic significance of marrow micrometastasis in women with early breast cancer. Eur J Surg. Oncol 1990; 16: 481-485.
18. Harbeck N, Untch M, Pache L, Eiermann W. Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up. Br J Cancer 1994; 69: 566-571.
19. Diel IJ et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 1996; 88: 1652-1664.
20. Cote RJ, Rosen PP, Lesser ML, Old LJ, Osborne MP. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastasis. J Clin Oncol 1991; 9: 1749-1756.
21. Singletary SE, Larry L, Trucker SL, Spitzer G. Detection of micrometastatic rumor cells in bone marrow of breast carcinoma patients. J Surg Oncol 1991; 47: 32-36.
22. Schlimok G et al. Prognostic significance of disseminated tumor cells detected in bone marrow of patients with breast and colorectal cancer: a multivariate analysis. Proc Am Soc Clin Oncol 1992; 11: 102 (abstract).
23. Braun S et al. Re: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 1998; 90: 1099-1100.
24. Sloane JP. Molecules and micrometastasis. Lancet 1995; 345: 1255-1256.
25. Pantel K et al. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother 1994; 3: 165-173.
26. Mansi JL, Berger U, Wilson P, Shearer R, Coombes RC. Detection of tumor cells in bone marrow of patients with prostatic carcinoma by immunocytochemical techniques. J Urology 1988; 139: 545-548.
27. Pantel K et al. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small cell lung cancer without overt metastasis. Lancet 1996; 347: 649-653.
28. Schlimok G et al. Epithelial tumor cells in bone marrow of patients with colorectal cancer: immunocytochemical detection, phenotypic characterization, and prognostic significance. J Clin Oncol 1990; 8: 831-837.
29. Braun S, Pantel K. Biological characteristics of micrometastatic carcinoma cells in bone marrow. In: Günthert U, Birchmeier W, (eds). Attempts to understand metastasis formation. Berlin-New York-Tokyo: Springer, 1996: Curr Top Microbiol Immunol; vol 213/I), pp 163-177.
30. Gallee MPW et al. Characterization of monoclonal antibodies raised against prostatic cell line PC-82. Prostate 1986; 9: 33-45.
31. Osborne M et al. Sensitivity of immunocytochemical detection of breast cancer cells in human bone marrow. Cancer Res 1991; 51: 2706-2709.
32. Molino A et al. A comparative analysis of three different techniques for the detection of breast cancer cells in bone marrow. Cancer 1991; 67: 1033-1036.
33. Jauch KW et al. Prognostic significance of bone marrow micrometastasis in patients with gastric cancer. J Clin Oncol 1996; 14: 1810-1817.
34. Diel IJ et al. Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis. J Clin Oncol 1992; 10: 1534-1539.
35. Schwarz G. Cytomorphology and cell yield in a new cytocentrifugal technique allowing the collection of the cell-free supernatant. Lab Med 1991; 15: 45-50.
36. Gribben JG, Freedman AS, Neuberg D. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation of B-cell lymphoma. N Engl J Med. 1991; 325: 1525-1533.
37. Bos IL. Ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-4689.
38. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993; 329: 1318-1327.
39. Hayashi N et al. Genetic diagnosis identifies occult lymph node metastasis undetectable by the histopathological method. Cancer Res 1994; 54: 3853-3856.
40. Hayashi N et al. Genetic diagnosis of lymph-node metastasis in colorectal cancer. Lancet 1995; 345: 1257-1259.
41. Datta YH, Adams PT, Drobyski WR. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol 1994; 12: 475-482.
42. Wood DP, Jr., Banks ER, Humphreys S, Rangnekar VM. Sensitivity of immunohistochemistry and polymerase chain reaction in detecting prostate cancer cells in bone marrow. J Histochem Cytochem 1994; 42: 505-511.
43. Zippelius A et al. Limitations of reverse transcriptase-polymerase chain reaction for detection of micrometastatic epithelial cancer cells in bone marrow. J Clin Oncol 1997; 15: 2701-2708.
44. Soeth E et al. Comprative analysis of bone marrow and venous blood isolates from gastrointestinal cancer patients for the detection of disseminated tumor cells using RT-PCR. Cancer Res 1997; 57: 3106.
45. Gerhard M et al. Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J Clin Oncol 1994; 12: 725-729.
46. De Graaf H, Maelandssmo GM, Ruud P, et al. Ectopic expression of target genes may represent an inherent limitation of RT-PCR assays used for micrometastasis detection: studies on the epithelial glycoprotein gene EGP-2. Int J Cancer 1997; 722: 191-196.
47. Krismann M et al. Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination. J Clin Oncol 1995; 13: 2769-2775.
48. Schoenfeld A et al. Detection of breast cancer micrometastasis in axillary lymph nodes by using Polymerase Chain Reaction. Cancer Res 1994; 54: 2986-2990.
49. Traweek ST, Liu J, Battifora H. Keratin gene expression in non-epithelial tissues. Detection with polymerase chain reaction. Am J Pathol 1993; 142: 1111-1118.
50. Fields KK et al. Clinical significance of bone marrow metastasis as detected using polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol 1996; 14: 1868-1876.
51. Pantel K et al. Association of cytokeratin-positive breast cancer micrometastasis with early recurrence and poor overall survival. Proc American Society of Clinical Oncology 1998; 17: 165a (abstr 633).
52. Lindemann F, Schlimok G, Dirschedl P, Witte J, Riethmüller G. Prognostic significance of micrometastaric tumour cells in bone marrow of colorectal cancer patients. Lancet 1992; 340: 685-689.
53. Juhl H et al. Immunocytological detection of micrometastatic cells: Comparative evaluation of findings in the peritoneal cavity and the bone marrow of gastric, colorectal and pancreatic cancer patients. Int J Cancer 1994; 57: 330-335.
54. Schlimok G et al. Micrometastatic tumor cells in bone marrow of patients with gastric cancer: methodological aspects of detection and prognostic significance. Eur J Cancer 1991; 27: 1461-1465.
55. Funke I et al. Comparative analyses of bone marrow micrometastasis in breast and gastric cancer. In J Cancer 1996; 65: 755-761.
56. Thorban S et al. Immunocytochemical detection of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma. J Natl Cancer Inst 1996; 88: 1222-1227.
57. Oberneder R et al. Prognostic relevance of micrometastatic tumor cells in bone marrow of patients with genitourinary tract tumors. J Urol 1994; 151: 413A (abstract).
58. Riesenberg R et al. Immunocytochemical double staining of cytokeratin and prostate specific antigen in individual prostatic tumor cells. Histochem. 1993; 99: 61-66.
59. Braun S, Hepp F, Janni W, Blankenstein T, Pantel K. Occult tumor cells immunocytochemically identified in bone marrow of patients with apparently localized ovarian cancer predict early distant metastatic relapse, 1999; submitted.
60. Karnby K et al. The presence of tumor cells in bone marrow at the time of first recurrence of breast cancer. Cancer 1987; 60: 1306-1312.
61. Berger U et al. The relationship between micrometastasis in the bone marrow, histopathologic features of the primary tumor in breast cancer and prognosis. Am J Clin Pathol 1988; 90: 1-6.
62. Cote RJ et al. Monoclonal antibodies detect occult breast carcinoma metastasis in the bone marrow of patients with early stage disease. Am J Surg Pathol 1988; 12: 333-340.
63. Taylor-Papadimitriou J, Burchell J, Moss F, Beverly P. Monoclonal antibodies to epithelial membrane antigen and human milk fat globule mucin define epitopes expressed on other molecules. Lancet 1985; 1: 458.
64. Heyderman E, Macartney JC. Epithelial membrane antigen and lymphoid cells. Lancet 1985; 1: 109.
65. Delsol G et al. Human lymphoid cells express epithelial membrane antigen. Lancet 1984, Nov 17; 2: 1124-1129.
66. Fox SB et al. Association of tumor angiogenesis with bone marrow micrometastasis in breast cancer. J Natl Cancer Inst 1997; 89: 1044-1049.
67. Bonnheim DC, Petrelli NJ, Herrera L, Walsh D, Mittelman A. Osseus metastasis from colorectal carcinoma. Am J Surg 1986; 151: 457-459.
68. Weiss L et al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol 1986; 150: 195-203.
69. Welch JP, Donaldson GA. The clinical correlation of an autopsy study of recurrent colorectal cancer. Ann Surg 1979; 189: 496-502.
70. Cannistra SA. Cancer of the ovary. N Engl J Med 1993; 329: 1550-1559.
71. Abdul-Karim FW et al. Bone metastasis from gynecologic carcinomas: a clinicopathologic study. Gynecol Oncol 1990; 39: 108-114.
72. Dauplat J et al. Distant metastasis in epithelial ovarian carcinoma. Cancer 1987; 60: 1561-1566.
73. Cain JM et al. Bone marrow involvement in epithelial ovarian cancer by immunocytochemical assessment. Gynecol Oncol 1990; 38: 442-445.
74. Ross AA et al. Immunocytochemical detection of tumor cells in bone marrow and peripheral blood stem cell collections from patients with ovarian cancer. Bone Marrow Transplant 1995; 15: 929-933.
75. Pantel K et al. Immunocytochemical monitoring of micrometastatic disease: reduction of prostate cancer cells in bone marrow by androgen deprivation. Int J Cancer 1997; 71: 521-525.
76. Dillman RO. Antibodies as cytotoxic therapy. J Clin Oncol 1994; 12: 1497-1515.
77. Braun S, Hepp F, Sommer HL, Pantel K. Tumor antigen heterogeneity of disseminated breast cancer cells: implications for immunotherapy of minimal residual disease. Int J Cancer 1999; 84: 1-5.
78. Braun S, Hepp F, Janni W, Sommer HL, Pantel K. Reduction of micrometastatic tumor load by monoclonal antibody therapy: influence of tumor antigen heterogeneity. Ann Oncol 1998; 9: 129 (abstr 621).
79. Schlimok G, Pantel K, Loibner H, Fackler-Schwalbe I, Riethmüller G. Reduction of metastatic carcinoma cells in bone marrow by intravenously administered monoclonal antibody: towards a novel surrogate test to monitor adjuvant therapies of solid tumours. Eur J Cancer 1995; 31A: 1799-1803.
80. Scholz D, Lubeck M, Loibner H. Biological activity in the human system of isotype variants of oligosaccharide Y-specific murine monoclonal antibodies. Cancer Immunol Immunother 1991; 33: 153-157.
81. Hempel D, Müller P, Oruzio D, Ehnle S, Schlimok G. Adoptive immunotherapy with monoclonal antibody 17-IA to reduce minimal residual disease in breast cancer patients after high-dose chemotherapy. Blood 1997; 90 (Suppl 1) 379B, abstract #4454.
82. Hohaus S et al. Persistence of isolated rumor cells in patients with breast cancer after sequential high-dose therapy with peripheral blood stem cell transplantation. Blood 1996; 88 (Suppl)10: 128A (abstract 501).
83. Jain RK Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990; 50: 2741-2451.
84. Riethmüller G, Johnson JP. Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancer. Curr Opin Immunol 1992; 4: 647-655.
85. Scott AM, Welt S. Antibody-based immunological therapies. Curr Opin Immunol 1997; 9: 717-722.
86. Funke I, Schraut W. Meta-analysis of studies on bone marrow micrometastasis: An independent prognostic impact remains to be substantiated. J Clin Oncol 1998; 16: 557-566.
87. Pantel K et al. Establishment of micrometastatic carcinoma cell lines: a novel source of tumor cell vaccines. J Natl Cancer Inst 1995; 87: 1162-1168.
88. Putz E et al. Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastasis. Cancer Res 1999; 59: 241-248.
89. Pantel K, Putz E, Riethmüller G. Identification of new therapeutic targets on bone marrow micrometastasis. Blood 1997; 90, (Suppl 1): 421A (abstract 1871).